Attention Deficit Disorder With Hyperactivity Clinical Trial
Official title:
Methylphenidate Treatment of ADHD in Children With Tourette Syndrome
This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder in children with both attention deficit hyperactivity disorder and Tourette syndrome.
Tourette syndrome is a neurological disorder that is characterized by repetitive,
involuntary movements and vocalizations called tics. Many children with Tourette syndrome
also have attention deficit hyperactivity disorder (ADHD), which is one of the most common
childhood mental disorders. Symptoms of ADHD usually include impulsiveness, inattention, and
hyperactivity. ADHD is commonly treated with a stimulant medication, such as
methylphenidate. It is under debate, however, whether using stimulants in children with
Tourette syndrome exacerbates tics associated with the disorder. This study will evaluate
the safety and effectiveness of methylphenidate in treating ADHD in children who have both
ADHD and Tourette syndrome.
Participants in this 6-week, double blind study will receive three doses of methylphenidate
over the course of the study. Each dose will be taken twice daily, approximately 3.5 hours
apart, for 2 weeks. Medication will be dispensed at study visits, which will occur once
every 2 weeks. At each study visit, participants will take a dose of the medication. About
an hour after ingesting the medication, they will be observed in a classroom setting by
study physicians. Participants will then complete a Continuous Performance Test, which will
measure their voluntary attention levels. The following will be assessed at study visits:
ADHD symptoms; oppositional and aggressive behavior; frequency and severity of tics and
obsessive compulsive disorder symptoms; rebound tic exacerbation; effects of methylphenidate
on tic-related problems with self-esteem, family life, academic and social performance, and
overall tic severity; anxiety and mood symptoms; and adverse drug reactions. Parents and
teachers will also complete assessments of participants' behavior on 2 days of each week for
the duration of the study.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00202605 -
Safety and Efficacy of SPD465 in Adults With ADHD
|
Phase 2 | |
Not yet recruiting |
NCT02677519 -
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
|
Phase 4 | |
Completed |
NCT02730572 -
Concerta (Methylphenidate) -To-Generic Switch Study
|
N/A | |
Completed |
NCT01681082 -
Psychological Effects of Tai Chi Training
|
N/A | |
Active, not recruiting |
NCT01330693 -
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
|
Phase 3 | |
Completed |
NCT00830700 -
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
|
N/A | |
Completed |
NCT00626236 -
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
|
Phase 2 | |
Completed |
NCT01012622 -
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
|
Phase 4 | |
Completed |
NCT00598182 -
Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study
|
N/A | |
Completed |
NCT00381407 -
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00178503 -
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
|
Phase 2/Phase 3 | |
Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
Completed |
NCT00218322 -
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
|
Phase 4 | |
Completed |
NCT00118911 -
Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00557011 -
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
|
Phase 2 | |
Completed |
NCT00071656 -
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
|
N/A | |
Active, not recruiting |
NCT00057668 -
Preventing Behavior Problems in Children With ADHD
|
Phase 2 | |
Completed |
NCT00050622 -
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT00050050 -
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
|
Phase 1 | |
Completed |
NCT00031395 -
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
|
Phase 3 |